WILMINGTON, Del., Sept. 29, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Concordia International Corp. (NASDAQ:CXRX)?
- Did you purchase your shares between November 12, 2015 and August 12, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Concordia International Corp. (“Concordia” or the “Company”) (NASDAQ:CXRX) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Concordia between November 12, 2015 and August 12, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public: (1) that the Company was experiencing a substantial increase in market competition against the Company’s drug, Donnatal, and other products; (2) that, as a result, the Company’s financial results would suffer and the Company would be forced to suspend its dividend; and (3) that, as a result of the foregoing, Defendants’ statements about Concordia’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
If you wish to serve as lead plaintiff, you must move the Court no later than October 14, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Concordia during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/concordia-international-corp-cxrx.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



